Journal
CANCER DISCOVERY
Volume 10, Issue 9, Pages 1296-1311Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-19-1416
Keywords
-
Categories
Funding
- Melanoma Research Foundation
- O'Connor-Macgregor Fund for Melanoma Research
- Stand Up To Cancer (SU2C) Innovative Research Grant [SU2C-AACR-IRG 16-17]
- BroadNext10
- NIH [R01CA227388]
- Damon Runyon Cancer Foundation Physician Scientist Training Grant
- Conquer Cancer Foundation
- Society for Immunotherapy of Cancer-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship
- NCI [P50CA101942]
- Damon Runyon-Rachleff Innovator Award
Ask authors/readers for more resources
The molecular mechanisms leading to resistance to PD-1 blockade are largely unknown. Here, we characterize tumor biopsies from a patient with melanoma who displayed heterogeneous responses to anti-PD-1 therapy. We observe that a resistant tumor exhibited a loss-of-function mutation in the tumor suppressor gene FBXW7, whereas a sensitive tumor from the same patient did not. Consistent with a functional role in immunotherapy response, inactivation of Fbxw7 in murine tumor cell lines caused resistance to anti-PD-1 in immunocompetent animals. Loss of Fbxw7 was associated with altered immune microenvironment, decreased tumor-intrinsic expression of the double-stranded RNA (dsRNA) sensors MDA5 and RIG1, and diminished induction of type I IFN and MHC-I expression. In contrast, restoration of dsRNA sensing in Fbxw7-deficient cells was sufficient to sensitize them to anti-PD-1. Our results thus establish a new role for the commonly inactivated tumor suppressor FBXW7 in viral sensing and sensitivity to immunotherapy. SIGNIFICANCE: Our findings establish a role of the commonly inactivated tumor suppressor FBXW7 as a genomic driver of response to anti-PD-1 therapy. Fbxw7 loss promotes resistance to anti-PD-1 through the downregulation of viral sensing pathways, suggesting that therapeutic reactivation of these pathways could improve clinical responses to checkpoint inhibitors in genomically defined cancer patient populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available